JD Health (06618) rose more than 4% in Hong Kong trading, with the stock climbing 4.39% to HK$51.15 by the time of writing. Turnover reached HK$159 million. The increase follows news that JD Health has entered a comprehensive strategic partnership with leading domestic medical device brand Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. The companies announced an ambitious three-year sales target of RMB 10 billion, aiming to set a new industry benchmark for growth. The collaboration will leverage JD Health's core capabilities in AI technology, digital services, supply chain management, and user operations to reshape medical devices through AI, drive product upgrades via technology, and redefine health experiences through ecosystem integration. Notably, the initial phase of cooperation will focus on two key areas: blood glucose management and respiratory health. In blood glucose management, the partners will jointly develop AI-powered data analysis and intervention alerts based on Yuyue's continuous glucose monitoring (CGM) systems, creating intelligent full-cycle management solutions for diabetes patients. For respiratory health, they plan to integrate AI algorithms into Yuyue's ventilators to enable smart recognition of respiratory events, adaptive adjustment of treatment parameters, and remote condition monitoring, ultimately improving user treatment experience and compliance.
Comments